Table 2.
Comparison of factors associated with duration of abiraterone treatment
| Factors | Median (mo), IQR | Events/ N | HR (95%CI) | P value |
|---|---|---|---|---|
| Duration of AA | Discontinuation of AA | |||
| Patients cohort | ||||
| Malaysia | 11.8 (5.9‐17.4) | 25/39 | 1.00 | |
| Thailand | 9.7 (4.6‐15.6) | 25/54 | 0.87 (0.50‐1.53) | .630 |
| Age at AA initiation (y) | 10 (5.6‐17.05) | 50/93 | 1.00 (0.97‐1.03) | .875 |
| Gleason score | ||||
| ≤7 | 11.4 (5.6‐19.8) | 17/39 | 1.00 | |
| >7 | 9.6 (5.4‐14.3) | 29/47 | 1.78 (0.97‐3.25) | .063 |
| ECOG status | ||||
| ≤1 | 11.5 (5.8‐17.4) | 33/68 | 1.00 | |
| >1 | 8.8 (5.2‐13.1) | 15/21 | 1.94 (1.05‐3.60) | .035 |
| Comorbidity count | ||||
| ≤1 | 9.7 (5.8‐16.7) | 32/62 | 1.00 | |
| >2 | 10.0 (4.4‐17.7) | 18/31 | 1.05 (0.59‐1.88) | .868 |
| Duration of primary ADT | ||||
| ≤30.3 mo | 8.3 (4.2‐14.2) | 25/45 | 1.00 | |
| >30.3 mo | 12.9 (6.6‐17.7) | 24/45 | 0.73 (0.41‐1.27) | .263 |
| Time from ADT to mCRPC | ||||
| ≤21 mo | 7.9 (4.6‐17.2) | 24/45 | 1.00 | |
| >21 mo | 12.0 (6.6‐17.0.0) | 25/44 | 0.98 (0.56‐1.74) | .950 |
| PSA doubling time | ||||
| ≤2.4 mo | 10.2 (4.7‐17.3) | 26/48 | 1.00 | |
| >2.4 mo | 9.8 (5.8‐17.2) | 21/41 | 0.95 (0.53‐1.69) | .857 |
| PSA at AA initiation | ||||
| ≤61 ng/mL | 12.5 (5.7‐17.5) | 16/45 | 1.00 | |
| >61 ng/mL | 9.5 (5.3‐16.9) | 33/46 | 2.31 (1.27‐4.20) | .006 |
| PSA response* | ||||
| No | 6.2 (3.5‐10.0) | 20/34 | 1.00 | |
| Yes | 13.6 (8.3‐22.0) | 24/47 | 0.43 (0.23‐0.79) | .006 |
| Chemotherapy status | ||||
| Chemo‐naïve | 10.6 (5.7‐17.2) | 33/69 | 1.00 | |
| Post‐chemo | 7.9 (3.8‐14.2) | 17/24 | 1.80 (1.00‐3.24) | .050 |
Abbreviations: AA, abiraterone acetate; ADT, androgen deprivation therapy; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; IQR, interquartile range; mCRPC, metastatic castrate‐resistant prostate cancer; PSA, prostate‐specific antigen.
*
≥50% PSA decline from baseline within 12 wks.
Colour shaded values indicates statistical significant P‐values.